Having trouble viewing this email? View in your browser.
ESCMID Logo

4 December 2018
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

EUCAST Rapid AST directly from blood culture bottles now available

EUCAST has published specific methods, QC criteria and breakpoints for rapid AST directly from positive blood culture bottles. The method has been developed to be robust enough to allow blood culture systems and other materials from several manufacturers. For several pathogens, disk diffusion plates can be read after 4 hours and for others after 6 or 8 hours. It is with currently used techniques probably not possible to perform faster phenotypic antimicrobial susceptibility testing. Read more about the fast method on http://www.eucast.org/rapid_ast_in_blood_cultures/ 

› Read more
 
OPEN CALLS | APPLICATIONS

ESCMID Postgraduate Education course on Foreign Body Infections announced – Groningen, Netherlands – 12-14 June, 2019

ESCMID is pleased to announce the Postgraduate Education Course “Update on diagnostic and clinical management of complex foreign body infections”, supported by EGIAI This course will bring together an expert faculty to discuss the diagnosis management of vascular graft and prosthetic joint infections, among other topics.

Click here to view the programme and to enrol in this exciting course.

Attendance grants are also available to ESCMID Young Scientist Members.

› Read more
Source: www.scandtick.com

The EU parliament has adopted a resolution on Lyme borreliosis

The ESCMID Study Group for Lyme Borreliosis welcomes the call of the EU parliament for additional epidemiological surveillance, funding and research for this tick-borne infection, and improvement of patient diagnosis and diagnostic testing.

Unfortunately, the resolution is based on exaggerated rumours such as “silent epidemic” spread by ticks, that remains underdiagnosed and affects around one million Europeans.

The ESGBOR would welcome support from the EU parliament addressing the issue of false rumours about Lyme borreliosis. It is also time to combat the provision of non-validated diagnostics testing, deceptive Lyme borreliosis diagnosis and inappropriate treatment. Causing unnecessary concern about a disease may also cause harm and is an important public health problem.

› Read more
 

CMI highlight: systematic review of statin use for the treatment of sepsis

The pleiotropic effect of hydroxymethylglutaryl-CoA reductase inhibitors (statins) might have a beneficial effect in sepsis through several mechanisms. Pertzov et al performed a systematic review to assess the efficacy and safety of statins, compared to placebo, for the treatment of sepsis in adults. They found 14 trials evaluating 2628 patients. In these studies, statins did not reduce 30-day all-cause mortality neither in all patients (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.83-1.10), nor in a subgroup of patients with severe sepsis (RR 0.97, 95% CI 0.84-1.12). The certainty of evidence for both outcomes was high. There was no change in the rate of adverse events between study arms (RR 1.24, 95% CI 0.94 to 1.63). The certainty of evidence for this outcome was high. The authors conclude that the use of statin therapy in adults for the indication of sepsis is not recommended.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.